Radiation sickness therapy set to begin human trials

The FDA has cleared Hollis-Eden to begin a Phase I trial of Neumene for radiation sickness. The initial study will focus on which dosages are likely to be effective in humans. The drug has worked in primate studies, reducing white blood cells and platelets in blood.

- read this story from the AP for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.